Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study

Janet Brown,Margaret A Paggiosi,Emma Rathbone,Walter Gregory,Gian Bertelli,Omar Din,Eugene McCloskey,David Dodwell,David Cameron,Richard Eastell,Robert Coleman
DOI: https://doi.org/10.1093/jbmr/zjad006
IF: 6.39
2024-01-04
Journal of Bone and Mineral Research
Abstract:Abstract Adjuvant bisphosphonates are often recommended in postmenopausal women with early breast cancer at intermediate-to-high risk of disease recurrence, but the magnitude and duration of their effects on bone mineral density (BMD) and bone turnover markers (BTMs) are not well described. We evaluated the impact of adjuvant zoledronate on areal BMD and BTMs in a sub-group of patients who had completed the large 5-yr randomized Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE) trial. About 224 women (recurrence free) who had completed the AZURE trial within the previous 3 mo were recruited from 20 UK AZURE trial sites. One hundred twenty had previously been randomized to zoledronate (19 doses of 4 mg over 5 yr) and 104 to the control arm. BMD and BTMs were assessed at sub-study entry, 6 (BTMs only), 12, 24, and 60 mo following the completion of AZURE. As expected, mean BMD, T-scores, and Z-scores at sub-study entry were higher in the zoledronate vs the control arm. At the lumbar spine, the mean (SD) standardized BMD (sBMD) was 1123 (201) and 985 (182) mg/cm2 in the zoledronate and control arms, respectively (P < .0001). The baseline differences in sBMD persisted at all assessed skeletal sites and throughout the 5-yr follow-up period. In patients completing zoledronate treatment, BTMs were significantly lower than those in the control arm (α- and β-urinary C-telopeptide of type-I collagen, both P < .00001; serum intact pro-collagen I N-propeptide, P < .00001 and serum tartrate-resistant acid phosphatase 5b, P = .0001). Some offset of bone turnover inhibition occurred in the 12 mo following the completion of zoledronate treatment. Thereafter, during the 60 mo of follow-up, all BTMs remained suppressed in the zoledronate arm relative to the control arm. In conclusion, in addition to the known anti-cancer benefits of adjuvant zoledronate, there are likely to be positive, lasting benefits in BMD and bone turnover.
endocrinology & metabolism
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate the long - term effects of adjuvant bisphosphonate therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in breast cancer patients. Specifically, through the BoHFAB study, the researchers aimed to understand how long the effects of this treatment on bone mineral density and bone turnover markers would last and the specific extent of these effects after the completion of 5 - year adjuvant zoledronic acid treatment. In addition, the study also explored the recovery of bone turnover inhibition after treatment cessation and evaluated the potential side effects of long - term zoledronic acid treatment. ### Research Background - **Breast Cancer and Bone Health**: Breast cancer treatment may lead to an increased risk of osteoporosis and fractures, especially in post - menopausal women. - **The Role of Bisphosphonates**: Bisphosphonates are a class of anti - resorptive drugs that can reduce bone loss and lower the risk of fractures, and are commonly used for the prevention and treatment of osteoporosis. In breast cancer patients, bisphosphonates are also used as adjuvant therapy to reduce the risk of disease recurrence and protect bone health. - **AZURE Trial**: This is a large - scale randomized controlled trial that evaluated the impact of adjuvant zoledronic acid treatment on the disease outcomes of stage II/III breast cancer patients. The results showed that 5 - year adjuvant zoledronic acid treatment could improve disease - free survival rate, reduce breast cancer mortality, and reduce the occurrence of fractures. ### Research Objectives - **Primary Endpoint**: To determine the mean percentage change difference in standardized bone mineral density (sBMD) of the lumbar spine between the zoledronic acid group and the control group 24 months after the completion of the treatment phase of the AZURE trial. - **Secondary Endpoints**: - To describe the mean differences in lumbar spine and total hip sBMD, serum PINP, TRAP5b, and urinary α - CTX and β - CTX at baseline between the two groups. - To compare the mean percentage change difference in total hip sBMD between the two groups at 24 months. - To compare the mean percentage changes in lumbar spine and total hip sBMD between the two groups at 12 and 60 months. - To compare the mean percentage changes in BTMs between the two groups at 6, 12, 24, 36, 48 and 60 months. ### Main Findings - **Bone Mineral Density**: After the completion of 5 - year zoledronic acid treatment, the sBMD of patients at all measured skeletal sites was significantly higher than that of the control group. This difference remained unchanged throughout the 5 - year follow - up period. - **Bone Turnover Markers**: In patients who completed zoledronic acid treatment, BTMs were inhibited at baseline and were significantly lower than those in the control group. Although a certain degree of relief of bone turnover inhibition was observed within 12 months after the end of treatment, all BTMs in the zoledronic acid group remained at relatively low levels during the subsequent 60 - month follow - up period, which were significantly lower than those in the control group. ### Conclusion This study confirmed that in addition to the known anti - tumor benefits, adjuvant zoledronic acid treatment may also bring positive and long - lasting benefits to bone mineral density and bone turnover. These findings further support the clinical practice of using bisphosphonates as adjuvant therapy in post - menopausal breast cancer patients.